Login / Signup

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.

Kohei ShitaraKei MuroJun WatanabeKentaro YamazakiHisatsugu OhoriManabu ShiozawaAtsuo TakashimaMitsuru YokotaAkitaka MakiyamaNaoya AkazawaHitoshi OjimaYasuhiro YuasaKeisuke MiwaHirofumi YasuiEiji OkiTakeo SatoTakeshi NaitohYoshito KomatsuTakeshi KatoIkuo MoriKazunori YamanakaMasamitsu HiharaJunpei SoedaToshihiro MisumiKouji YamamotoRiu YamashitaKiwamu AkagiAtsushi OchiaiHiroyuki UetakeKatsuya TsuchiharaTakayuki Yoshino
Published in: Nature medicine (2024)
Certain genetic alterations and right-sided primary tumor location are associated with resistance to anti-epidermal growth factor (EGFR) treatment in metastatic colorectal cancer (mCRC). The phase 3 PARADIGM trial (n = 802) demonstrated longer overall survival with first-line anti-EGFR (panitumumab) versus antivascular endothelial growth factor (bevacizumab) plus modified FOLFOX6 in patients with RAS wild-type mCRC with left-sided primary tumors. This prespecified exploratory biomarker analysis of PARADIGM (n = 733) evaluated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes, focusing on a broad panel of gene alterations associated with resistance to EGFR inhibition, including KRAS, NRAS, PTEN and extracellular domain EGFR mutations, HER2 and MET amplifications, and ALK, RET and NTRK1 fusions. Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA that lacked gene alterations in the panel (that is, negative hyperselected; median in the overall population: 40.7 versus 34.4 months; hazard ratio, 0.76; 95% confidence interval, 0.62-0.92) but was similar or inferior with panitumumab in patients with ctDNA that contained any gene alteration in the panel (19.2 versus 22.2 months; hazard ratio, 1.13; 95% confidence interval, 0.83-1.53), regardless of tumor sidedness. Negative hyperselection using ctDNA may guide optimal treatment selection in patients with mCRC. ClinicalTrials.gov registrations: NCT02394834 and NCT02394795 .
Keyphrases